PatientsVille.com Logo


Fluconazol Medical Research Studies

Up-to-date List of Fluconazol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Fluconazol Medical Research Studies

Rank Status Study
1 Recruiting Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder
Condition: HIV Associated Neurocognitive Disorder
Interventions: Drug: Fluconazole;   Drug: Paroxetine;   Drug: Paroxetine and Fluconazole;   Drug: Placebo
Outcome Measures: CSF lipid and protein markers of oxidative stress;   Neurocognitive performance;   Functional performance;   Magnetic resonance spectroscopy (MRS) and arterial spin labeling
2 Unknown  Study of Fluconazole in Children With Autism Spectrum Disorder
Condition: Autism Spectrum Disorder
Intervention: Drug: Fluconazole
Outcome Measure: PDD Behavior Inventory
3 Not yet recruiting Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants
Conditions: Ductus Arteriosis, Patent;   Bacterial Infections and Mycoses
Interventions: Drug: Treatment with Fluconazole.;   Drug: 2. Treatment with both Fluconazole and Ibuprofen.;   Drug: 3. Treatment with ibuprofen.;   Other: 4. No treatment with either Fluconazole nor ibuprofen.
Outcome Measures: Urinary concentrations of prostacycline (PGI2) and thromboxane A2 (TxA2) measured in picogram/milliliter.;   Concentration of thromboxane A2 (TXA2) and prostacycline (PGI2) in relation to genetic variation of the enzymes of the Cytochrome (P4502C) family.;   Number of and type of Adverse Drug Reactions
4 Not yet recruiting High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
Condition: Cutaneous Leishmaniasis
Interventions: Drug: Fluconazole;   Drug: Meglumine Antimoniate
Outcome Measures: Cure rate or complete cicatrization of the ulcer.;   Initial cure rate or complete cicatrization of the ulcer
5 Recruiting High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Conditions: Cryptococcal Meningitis;   HIV Infections
Interventions: Drug: Fluconazole;   Drug: Amphotericin B
Outcome Measures: Discontinuation of study-provided Fluconazole or ampho B, including precipitating and surrounding adverse events;   Qualitative and quantitative CSF culture results at entry, Week 2, and when conducted thereafter;   Survival;   Results of the neurological examination;   Length of hospitalization;   Recurrence/relapse of CM based on clinical presentation;   CNS immune reconstitution inflammatory syndrome (IRIS);   Additional safety parameters including: Grade 3 and 4 adverse events; dose modifications; duration of temporary treatment interruptions; permanent discontinuation of either agent;   Results of functional status evaluation;   Number and nature of hospital readmissions
6 Recruiting Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Fungal Infection;   Neutropenia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: caspofungin acetate;   Drug: Fluconazole;   Other: laboratory biomarker analysis
Outcome Measures: Time to development of proven or probable invasive fungal infections (IFI), defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG);   Time to development of proven or probably invasive aspergillosis (IA), defined according to the criteria developed by the EORTC/MSG;   Time to death due to any cause;   Total days of empiric antifungal therapy while a patient is receiving prophylaxis;   Sensitivity, specificity, positive predictive value, and negative predictive value of the galactomannan and beta-D glucan assays for the diagnosis of IFI or IA alone;   Results of the genotyping assays for single nucleotide polymorphism analysis
7 Not yet recruiting Fluconazole Versus Micafungin in Neonates With Candidiasis
Condition: Candidiasis
Interventions: Drug: Fluconazole;   Drug: Micafungin
Outcome Measure: Area Under the Concentration / Minimal Inhibitory Concentration ratio (AUC/MIC ratio)
8 Recruiting Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients
Condition: Liver Transplant Recipient
Interventions: Drug: micafungin;   Drug: Fluconazole
Outcome Measures: Prevention of invasive fungal disease;   no events of proven/probable IFD;   ime to proven/probable IFD;   fungal-free survival;   incidence of superficial mycosis infection and colonization;   saftey by variables;   cases of adverse events
9 Recruiting Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Interventions: Drug: MLN4924;   Drug: Fluconazole;   Drug: Itraconazole;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Paclitaxel
Outcome Measures: Cmax: Maximum Observed Plasma Concentration for MLN4924 (Part A);   AUC(0-tlast): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for MLN4924 (Part A);   AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN4924 (Part A);   Number of Participants With Treatment-Emergent Adverse Events (TEAEs);   Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings;   Body Weight Measurements (Part A);   Number of Participants With Potentially Clinically Significant Vital Sign Findings;   Clearance (CL) Pharmacokinetic Parameter (Part A);   Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN4924 (Part A);   Volume-Steady State (Vss) Pharmacokinetic Parameter (Part A);   Terminal Elimination Half-life (T1/2) Pharmacokinetic Parameter for MLN4924 (Part A);   Blood to plasma (B/P) ratio for MLN4924 (Part A);   Measurement of Disease Response (Part B)
10 Recruiting Pharmacokinetic Study of Fluconazole in Premature Infants
Condition: Very Low Birth Weight Infant
Intervention: Drug: Fluconazole
Outcome Measure: drug level of Fluconazole
11 Recruiting Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Conditions: Congenital Combined Immunodeficiency;   Fungal Infection;   Hematopoietic/Lymphoid Cancer;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: caspofungin acetate;   Drug: Fluconazole;   Drug: voriconazole;   Other: laboratory biomarker analysis
Outcome Measure: Development of proven or probable IFI defined according to criteria developed by the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG)
12 Recruiting Operational Research for Cryptococcal Antigen Screening
Conditions: Cryptococcal Meningitis;   Cryptococcus Neoformans;   Cryptococcosis
Intervention: Drug: Fluconazole
Outcome Measures: Retention in care;   Cryptococcal meningitis-free survival time;   Survival Time;   Uptake of CRAG screening and preemptive treatment;   Time from CRAG+ test to receipt of Fluconazole therapy;   All-cause discontinuation of Fluconazole;   Percentage of participants with symptomatic cryptococcal meningitis;   Risk factors for symptomatic cryptococcal meningitis
13 Unknown  Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis
Condition: Vaginal Candidiasis
Interventions: Drug: Probiotics (Natural product);   Drug: Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
Outcome Measures: In the placebo group of patients, it is anticipated that at the 3 month period, a recurrence rate of 50% will occur, whereas, in the treatment arm a reduction in recurrence to 25% will be achieved;   Reduction in clinic visits for urogenital care and cost savings
14 Recruiting Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
Conditions: Stem Cell Transplantation;   Graft vs Host Disease
Interventions: Drug: Budesonide;   Drug: Fluconazole;   Drug: Voriconazole
Outcome Measure: The primary endpoints are the Cmin and Cmax of budesonide
15 Recruiting Study To Assess The Safety, Pharmacokinetics, And Evaluate The Response To Anidulafungin When Treating Children With Invasive Candidiasis
Condition: Candidemia
Interventions: Drug: anidulafungin;   Drug: Fluconazole
Outcome Measures: To assess the safety and tolerability of anidulafungin when used to treat children with invasive candidiasis, including candidemia.;   To assess rates of relapse at the Week 2 and Week 6 FU visits;   To assess all-cause mortality at the EOIVT and EOT time points;   To explore pharmacokinetic parameters of anidulafungin in children aged 1 month to <2 years following IV infusion of anidulafungin (area under curve over dosing interval (AUC24) and peak concentration (Cmax));;   To assess the efficacy of anidulafungin, as measured by global response, at the following time points: EOIVT, EOT, 2-week FU visit and 6-week FU visit;   To explore the exposure-response (safety and efficacy endpoints) relationship of anidulafungin using a nonlinear mixed effects approach as appropriate, including exploring the association between PK-PD index (eg, AUC/MIC) and efficacy endpoints;;   To assess rates of emerging infection at the Week 2 and Week 6 FU visits
16 Recruiting Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy
Condition: Human Immunodeficiency Virus
Interventions: Drug: Raltegravir;   Drug: Fluconazole;   Drug: Azithromycin;   Drug: Albendazole;   Drug: Isoniazid;   Dietary Supplement: Ready to Use Supplementary Food
Outcome Measures: All-cause mortality over the first 24 weeks after starting ART;   48 week mortality (all-cause);   Safety;   Hospital inpatient episodes and total days admitted;   Adherence to ART and acceptability of each strategy;   Endpoint relating to anti-infection intervention;   Endpoint relating to anti-malnutrition intervention;   Endpoint relating to anti-HIV intervention
17 Recruiting Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation
Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study;   Procedure: Collection of blood and tissues;   Procedure: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), K+ counter, ultrasound, MRI;   Drug: Humatrope;   Drug: Ketoconazole;   Drug: Oxandrolone;   Drug: Propranolol;   Drug: Oxandrolone and propranolol combined;   Drug: Humatrope and propranolol combined;   Drug: Placebo;   Behavioral: Exercise--Hospital supervised intensive exercise program;   Behavioral: Home exercise program
Outcome Measure: Outcome assessments will include measures of muscle wasting, weakness, immunosuppression chronic bone loss and decreased growth with increases in metabolic, hemodynamic, inflammatory and scarring responses.
18 Recruiting International Pediatric Fungal Network
Condition: Pediatric Invasive Candidiasis
Intervention: Drug: Observational antifungal therapy
Outcome Measures: Global response to antifungal therapy at day 14;   Global response of antifungal therapy at day 35;   All-cause mortality;   Development of candidemia while in PICU
19 Recruiting Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis
Condition: Cryptococcal Meningitis
Interventions: Drug: Liposomal amphotericin B;   Drug: Amphotericin B-deoxycholate
Outcome Measure: suscceful response rate
20 Unknown  Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week
Condition: Pulmonary Candidiasis
Intervention: Drug: Fluconazole
Outcome Measure: invasive candidiasis

These studies may lead to new treatments and are adding insight into Fluconazol etiology and treatment.

A major focus of Fluconazol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Fluconazol